0001104659-23-011499.txt : 20230207 0001104659-23-011499.hdr.sgml : 20230207 20230207074324 ACCESSION NUMBER: 0001104659-23-011499 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230206 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230207 DATE AS OF CHANGE: 20230207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: First Wave BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464993860 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37853 FILM NUMBER: 23592790 BUSINESS ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-589-7020 MAIL ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AzurRx BioPharma, Inc. DATE OF NAME CHANGE: 20141103 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 8-K 1 tm235300d1_8k.htm FORM 8-K
0001604191 false 0001604191 2023-02-06 2023-02-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 6, 2023

 

First Wave BioPharma, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   001-37853   46-4993860
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (IRS Employer Identification No.)

 

777 Yamato Road, Suite 502

Boca Raton, Florida

   33431
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (561) 589-7020

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which

registered

Common Stock, par value $0.0001 per share   FWBI   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 


On February 7, 2023, First Wave BioPharma, Inc. (the “Company”) issued a press release announcing the Nasdaq Hearing Panel (the “Panel”) had notified the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule") and advised that the Panel's oversight process of the Company is now closed. A copy of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 8.01 Other Events.

 

Nasdaq Compliance

 

As previously reported, on December 14, 2022, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating the Company was not in compliance with the Minimum Bid Price Rule to maintain a minimum bid price of $1.00 per share for its common stock.

 

On February 6, 2023, the Company received a letter from the Panel indicating that the Company has regained compliance with the Minimum Bid Price Requirement and that the Panel's oversight process of the Company is now closed.

 

Risk Factor

 

The Company is including the below update to its risk factors, for the purpose of supplementing and updating the disclosure contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2022 (as amended on Form 10-K/A filed with the SEC on May 10, 2022) and its Quarterly Reports on Form 10-Q for the periods ended March 31, 2022, filed with the SEC on May 23, 2022, June 30, 2022, filed with the SEC on August 15, 2022, and September 30, 2022, filed with the SEC on November 13, 2022.

 

Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our Common Stock.

 

Our common stock is currently listed for trading on The Nasdaq Capital Market. We must satisfy the continued listing requirements of Nasdaq to maintain the listing of our common stock on The Nasdaq Capital Market.

 

As we have previously reported, on November 26, 2021, we received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that we were not in compliance with the $2.5 million minimum stockholders’ equity requirement for continued listing of our common stock on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Rule”).

 

On January 10, 2022, we submitted a plan to the Staff to regain compliance with the Minimum Stockholders’ Equity Rule and on February 15, 2022, the Staff notified us that Nasdaq had granted us an extension through May 25, 2022, to regain compliance. On May 26, 2022, we received a letter from the Staff indicating that, based upon our continued non-compliance with the Minimum Stockholders’ Equity Rule, the Staff had determined to delist the Company’s securities from The Nasdaq Capital Market unless we timely requested a hearing before a Nasdaq Hearing Panel (the “Panel”).

 

Additionally, on May 16, 2022, we received notice from the Staff indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we were not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). We had 180 days from May 16, 2022, or through November 14, 2022, to regain compliance with the Bid Price Rule. After receiving stockholder approval at the annual meeting of stockholders on August 26, 2022, we effected a one-for-thirty reverse stock split of our common stock. By letter dated September 12, 2022, the Staff advised us that we had regained compliance with the Bid Price Rule.

 

 

 

 

We timely requested a hearing before the Panel. Following the hearing, on July 11, 2022, the Panel granted our request for continued listing of our common stock (the “Exception”). The Exception was subject to a number of significant conditions that must be satisfied on or before specific deadlines set forth in the Exception, including the completion of one or more significant equity financings on terms described in the Exception. The final term of the Exception expired on November 22, 2022. As previously reported, on November 22, 2022, we closed a private placement offering for gross proceeds of approximately $2.5 million. As a result of that financing, we filed a Current Report on Form 8-K on December 16, 2022, stating, as of the date of that filing, we believed that we had stockholders’ equity in excess of the $2.5 million required under the Minimum Stockholders’ Equity Rule. On December 20, 2022, we received a letter from the Panel confirming that the Company had regained compliance with the Minimum Stockholders’ Equity Rule.

  

On December 14, 2022, we received notice from the Staff indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we were not in compliance with the Bid Price Rule. After receiving stockholder approval at a special meeting of stockholders on January 13, 2023, we effected a one-for-seven reverse stock split of our common stock. By letter dated February 6, 2023, the Panel advised us that we had regained compliance with the Bid Price Rule and that the matter was closed.

 

There can be no assurance that we will be able to sustain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. In the event that we are unable to comply with The Nasdaq Capital Market’s continued listing standards, our common stock may be delisted from The Nasdaq Capital Market.

 

Additionally, in 2020, the SEC approved a previously proposed Nasdaq rule change to expedite delisting of securities with a closing bid price at or below $0.10 for 10 consecutive trading days during any bid price compliance period and that have had one or more reverse stock splits with a cumulative ratio of one for 250 or more shares over the prior two-year period. In addition, if a company falls out of compliance with the $1.00 minimum bid price after completing reverse stock splits over the immediately preceding two years that cumulatively result in a ratio one for 250 shares, the company will not be able to avail itself of any bid price compliance periods under Rule 5810(c)(3)(A), and Nasdaq will instead require the issuance of a Staff delisting determination. We could appeal the determination to a hearings panel, which could grant us a 180-day exception to remain listed if it believes we would be able to achieve and maintain compliance with the bid price requirement. We believe that we would be subject to these procedures applicable to a company with recurring deficiencies (Nasdaq Rule 5815(d)(4)(B)).

 

If our common stock were delisted from The Nasdaq Capital Market, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules as a “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. In addition, delisting would materially and adversely affect our ability to raise capital on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital.

 

 

 

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No. Description
99.1 Press Release, dated February 7, 2023.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  First Wave BioPharma, Inc.
   
February 7, 2023 By: /s/ James Sapirstein
  Name: James Sapirstein
  Title: Chief Executive Officer

 

 

 EX-99.1 2 tm235300d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

First Wave BioPharma Regains Compliance With Nasdaq’s Minimum Bid Price Requirement

 

Nasdaq Panel Oversight Process Closed

 

BOCA RATON, Fla., Feb. 7, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that on February 6, 2023, the Company received formal notice from the Nasdaq Hearing Panel (the “Panel”) indicating that First Wave BioPharma has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and advised that the Panel’s oversight process of the Company is now closed. The Panel previously notified the Company on December 20, 2022, that the Company had regained compliance with the minimum stockholders’ equity requirement (the “Minimum Stockholders’ Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1) based on the Company’s representation that following the closing of its private placement offering for gross proceeds of approximately $2.5 million on November 22, 2022, the Company believed it had stockholders’ equity in excess of the $2.5 million required under the Minimum Stockholders’ Equity Requirement.

 

“Maintaining our Nasdaq listing is key to our growth strategy and our efforts to generate long-term shareholder value by expanding awareness of First Wave BioPharma within the investment community,” stated James Sapirstein, Chairman, President and CEO of First Wave BioPharma.

 

About First Wave BioPharma, Inc.

 

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

 

 

 

 

Forward-Looking Statement

 

This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able maintain compliance with Nasdaq’s continued listing criteria and the effect of a delisting from Nasdaq on the market for the Company’s securities; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company’s business, operating results and financial prospects; and the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

 

For more information:

First Wave BioPharma, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
investors@firstwavebio.com

 

Media contact:

Tiberend Strategic Advisors, Inc.
David Schemelia: (609) 468-9325

dschemelia@tiberend.com

Bill Borden: (732) 910-1620
bborden@tiberend.com

 

 

 

 EX-101.SCH 3 fwbi-20230206.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 fwbi-20230206_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 fwbi-20230206_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 06, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 06, 2023
Entity File Number 001-37853
Entity Registrant Name First Wave BioPharma, Inc.
Entity Central Index Key 0001604191
Entity Tax Identification Number 46-4993860
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 777 Yamato Road
Entity Address, Address Line Two Suite 502
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33431
City Area Code 561
Local Phone Number 589-7020
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol FWBI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tm235300d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001604191 2023-02-06 2023-02-06 iso4217:USD shares iso4217:USD shares 0001604191 false 8-K 2023-02-06 First Wave BioPharma, Inc. DE 001-37853 46-4993860 777 Yamato Road Suite 502 Boca Raton FL 33431 561 589-7020 false false false false Common Stock, par value $0.0001 per share FWBI NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://firstwavebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm235300d1_8k.htm fwbi-20230206.xsd fwbi-20230206_lab.xml fwbi-20230206_pre.xml tm235300d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm235300d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm235300d1_8k.htm" ] }, "labelLink": { "local": [ "fwbi-20230206_lab.xml" ] }, "presentationLink": { "local": [ "fwbi-20230206_pre.xml" ] }, "schema": { "local": [ "fwbi-20230206.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "FWBI", "nsuri": "http://firstwavebio.com/20230206", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm235300d1_8k.htm", "contextRef": "From2023-02-06to2023-02-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://firstwavebio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm235300d1_8k.htm", "contextRef": "From2023-02-06to2023-02-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-011499-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-011499-xbrl.zip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